Results 41 to 50 of about 4,590 (196)
The Relationship Between Insulin Resistance Neutrophil to Lymphocyte Ratio [PDF]
arXiv, 2022 Aim: There is increasing interest in the role of chronic inflammation on pathogenesis of various disease, and one of its markers, high NLR is associated with various mortality and morbidity risk. Insulin resistance (IR) might be one potential associate factors, as suggested in preclinical studies.
arxiv
Conversion from insulin glargine U-100 to insulin glargine U-300 or insulin degludec and the impact on dosage requirements [PDF]
Therapeutic Advances in Endocrinology and Metabolism, 2018 Background: We wanted to determine whether basal insulin requirements change when patients transition from insulin glargine U-100 (Gla-100) to insulin glargine U-300 (Gla-300) or insulin degludec. Methods: This study involved subjects seen in the University of Colorado Health Endocrine Clinic who were transitioned from Gla-100 to either Gla-300 ( n ...
Scott M. Pearson, Jennifer M. Trujillo
openaire +4 more sources
Australian and New Zealand Journal of Obstetrics and Gynaecology, EarlyView.ABSTRACT Background In patients with diabetes, antenatal glucocorticoids can induce transient maternal hyperglycaemia for approximately 72 h. This may be associated with adverse outcomes, including neonatal hypoglycaemia, prompting recommendations for prophylactic increases in insulin by some expert groups; however, there are no validated protocols.
Annabel Jones +6 more
wiley +1 more source
Intermittent Control for Safe Long-Acting Insulin Intensification for Type 2 Diabetes: In-Silico Experiment [PDF]
arXiv, 2023 Around a third of type 2 diabetes patients (T2D) are escalated to basal insulin injections. Basal insulin dose is titrated to achieve a tight glycemic target without undue hypoglycemic risk. In the standard of care (SoC), titration is based on intermittent fasting blood glucose (FBG) measurements.
arxiv
An overview of insulin therapy for the non‐specialist
Diabetes, Obesity and Metabolism, EarlyView.Abstract Nearly all health professionals, whatever their practice or speciality, now have contact with a significant number of insulin‐using people with diabetes. People with type 1 diabetes are nearly universally managed on more complex insulin regimens, increasingly with complex support technology, and with some understanding of the concepts ...
Philip D. Home
wiley +1 more source
Effects of insulin and analogues on carcinogen-induced mammary tumours in high-fat-fed rats
Endocrine Connections, 2018 It is not fully clarified whether insulin glargine, an analogue with a high affinity for insulin-like growth factor-1 receptor (IGF-1R), increases the risk for cancers that abundantly express IGF-1R such as breast cancer or some types of breast cancer ...
Yusaku Mori +8 more
doaj +1 more source
BMC Endocrine Disorders, 2021 Background MYL-1501D is a proposed biosimilar to insulin glargine. The noninferiority of MYL-1501D was demonstrated in patients with type 1 diabetes and type 2 diabetes in 2 phase 3 trials.
Bin Sun +11 more
doaj +1 more source
Biosimilar insulins: Narrative review of the regulatory framework and registration studies
Diabetes, Obesity and Metabolism, EarlyView.Abstract Biosimilar insulins have been commercially available in the EU since 2014. Currently, six biosimilar insulins are approved in the EU and four in the US. However, commercial success has been limited, which may be in part due to concerns among physicians and people with diabetes that biosimilar insulins are substandard in efficacy, safety, and ...
Tim Heise, J. Hans DeVries
wiley +1 more source
Journal of Diabetes Research, 2019 Background. This study is aimed at estimating the proportion of type 2 diabetes mellitus (T2DM) patients treated with basal insulin (insulin glargine U100) and at evaluating daily insulin dose, treatment pattern, and adherence to treatment of these ...
Luca Degli Esposti +10 more
doaj +1 more source
Reduced Hypoglycemia Risk With Insulin Glargine [PDF]
Diabetes Care, 2005 OBJECTIVE—Insulin glargine (LANTUS) is a once-daily basal insulin analog with a smooth 24-h time-action profile that provides effective glycemic control with reduced hypoglycemia risk (particularly nocturnal) compared with NPH insulin in patients with type 2 diabetes.
Alan Salzman +5 more
openaire +3 more sources